Clinicians should consider both cultural practices and genetic factors when diagnosing and treating pediatric skin conditions ...
Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...
In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...
Sunlight often gets a bad reputation, especially at a dermatology conference, but as experts emphasized during this morning’s ...
Rewarding and incentivizing physicians to provide high quality care at a lower cost — who can object to that? The idea of value-based care is as attractive to dermatologists as it is to other ...
Developed by Incyte Corp., Opzelura is a topical nonsteroidal that is approved for patients 2 years of age and older with mild-to-moderate atopic dermatitis. It is a selective JAK1/JAK2 inhibitor that ...
This evening’s session at the 2026 American Academy of Dermatology Annual Meeting focused on an often-overlooked culprit in dermatology: arthropods. Titled “What’s Bugging You? Arthropods of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results